May 29, 2020
The Japan unit of Amgen said on May 28 that its anti-CGRP receptor antibody erenumab met the primary endpoint in a PIII study enrolling Japanese patients with chronic and episodic migraines. In the study, which compared erenumab to placebo in...read more